<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01478737</url>
  </required_header>
  <id_info>
    <org_study_id>PDRPOZU1</org_study_id>
    <nct_id>NCT01478737</nct_id>
  </id_info>
  <brief_title>Intravitreal Ozurdex After Pars Plana Vitrectomy for Proliferative Diabetic Retinopathy</brief_title>
  <official_title>A Prospective, Randomized Study on Intravitreal Ozurdex for Preventing Recurrent Vitreous Hemorrhage Following Pars Plana Vitrectomy for Proliferative Diabetic Retinopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Anders Kvanta</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Erik Eye Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate if intravitreal Ozurdex can reduce the incidence of recurrent vitreous hemorrhage
      after primary pars plana vitrectomy (PPV) in patients with proliferative diabetic retinopathy
      (PDRP).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To perform a randomized, controlled, study on patients that undergo PPV for vitreous
      hemorrhage secondary to PDRP. Half of the patients will receive an intravitreal Ozurdex
      implant immediately after surgery. The primary outcome measure is the proportion of patients
      that, due to rebleeding within 12 months, have a second PPV. Secondary outcome measures
      include the number of episodes of vitreous hemorrhage that occur within 12 months after
      surgery but clear spontaneously.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2011</start_date>
  <completion_date type="Anticipated">September 2015</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reoperation</measure>
    <time_frame>12 months</time_frame>
    <description>The proportion of patients that, due to re-bleeding within 12 months, have a second PPV</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rebleeding</measure>
    <time_frame>12 months</time_frame>
    <description>The number of episodes of vitreous hemorrhage that occur within 12 months after surgery but clear spontaneously</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Proliferative Diabetic Retinopathy</condition>
  <arm_group>
    <arm_group_label>Sham</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Vitrectomy only</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intravitreal Ozurdex</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intravitreal Ozurdex after vitrectomy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravitreal dexamethasone implant</intervention_name>
    <description>Intravitreal Ozurdex after vitrectomy</description>
    <arm_group_label>Intravitreal Ozurdex</arm_group_label>
    <other_name>OZURDEXÂ® (dexamethasone intravitreal implant)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Vitrectomy</intervention_name>
    <description>Vitrectomy only</description>
    <arm_group_label>Sham</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with vitreous hemorrhage undergoing PPV for PDRP

        Exclusion Criteria:

          -  Previous PPV

          -  Vitreous hemorrhage of non-PDRP origin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anders Kvanta, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Erik Eye Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anders Kvanta, PhD</last_name>
    <email>anders.kvanta@sankterik.se</email>
  </overall_contact>
  <location>
    <facility>
      <name>St. Erik Eye Hospital</name>
      <address>
        <city>Stockholm</city>
        <state>NonUS</state>
        <zip>11282</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anders Kvanta, PhD</last_name>
      <email>anders.kvanta@sankterik.se</email>
    </contact>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 21, 2011</study_first_submitted>
  <study_first_submitted_qc>November 22, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 23, 2011</study_first_posted>
  <last_update_submitted>September 24, 2014</last_update_submitted>
  <last_update_submitted_qc>September 24, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 25, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>St. Erik Eye Hospital</investigator_affiliation>
    <investigator_full_name>Anders Kvanta</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>PDRP</keyword>
  <keyword>vitreous hemorrhage</keyword>
  <keyword>vitrectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Diabetic Retinopathy</mesh_term>
    <mesh_term>Vitreous Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

